Celldex Therapeutics, Inc. TCE2.F Stock
Celldex Therapeutics, Inc. Price Chart
Celldex Therapeutics, Inc. TCE2.F Financial and Trading Overview
Celldex Therapeutics, Inc. stock price | 37.8 EUR |
Previous Close | 34.6 EUR |
Open | 33.4 EUR |
Bid | 33.4 EUR x 0 |
Ask | 33.8 EUR x 0 |
Day's Range | 33.4 - 33.4 EUR |
52 Week Range | 21.2 - 43.44 EUR |
Volume | 500 EUR |
Avg. Volume | 14 EUR |
Market Cap | 1.58B EUR |
Beta (5Y Monthly) | 2.127816 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.72 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 64.83 EUR |
TCE2.F Valuation Measures
Enterprise Value | 1.36B EUR |
Trailing P/E | N/A |
Forward P/E | -19.306358 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 501.02655 |
Price/Book (mrq) | 5.212235 |
Enterprise Value/Revenue | 431.809 |
Enterprise Value/EBITDA | -12.041 |
Trading Information
Celldex Therapeutics, Inc. Stock Price History
Beta (5Y Monthly) | 2.127816 |
52-Week Change | 66.03% |
S&P500 52-Week Change | 20.43% |
52 Week High | 43.44 EUR |
52 Week Low | 21.2 EUR |
50-Day Moving Average | 30.49 EUR |
200-Day Moving Average | 34.62 EUR |
TCE2.F Share Statistics
Avg. Volume (3 month) | 14 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 47.25M |
Float | 44.02M |
Short Ratio | N/A |
% Held by Insiders | 0.30% |
% Held by Institutions | 105.54% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -3675.36% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -19.33% |
Return on Equity (ttm) | -33.85% |
Income Statement
Revenue (ttm) | 3.15M EUR |
Revenue Per Share (ttm) | 0.07 EUR |
Quarterly Revenue Growth (yoy) | 455.70% |
Gross Profit (ttm) | -79901000 EUR |
EBITDA | -112963000 EUR |
Net Income Avi to Common (ttm) | -118636000 EUR |
Diluted EPS (ttm) | -2.59 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 278.39M EUR |
Total Cash Per Share (mrq) | 5.89 EUR |
Total Debt (mrq) | 3.65M EUR |
Total Debt/Equity (mrq) | 1.21 EUR |
Current Ratio (mrq) | 19.029 |
Book Value Per Share (mrq) | 6.408 |
Cash Flow Statement
Operating Cash Flow (ttm) | -107767000 EUR |
Levered Free Cash Flow (ttm) | -54598752 EUR |
Profile of Celldex Therapeutics, Inc.
Country | Germany |
State | NJ |
City | Hampton |
Address | Perryville III Building |
ZIP | 08827 |
Phone | 908 200 7500 |
Website | https://www.celldex.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 148 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. It has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Q&A For Celldex Therapeutics, Inc. Stock
What is a current TCE2.F stock price?
Celldex Therapeutics, Inc. TCE2.F stock price today per share is 37.8 EUR.
How to purchase Celldex Therapeutics, Inc. stock?
You can buy TCE2.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Celldex Therapeutics, Inc.?
The stock symbol or ticker of Celldex Therapeutics, Inc. is TCE2.F.
Which industry does the Celldex Therapeutics, Inc. company belong to?
The Celldex Therapeutics, Inc. industry is Biotechnology.
How many shares does Celldex Therapeutics, Inc. have in circulation?
The max supply of Celldex Therapeutics, Inc. shares is 65.7M.
What is Celldex Therapeutics, Inc. Price to Earnings Ratio (PE Ratio)?
Celldex Therapeutics, Inc. PE Ratio is now.
What was Celldex Therapeutics, Inc. earnings per share over the trailing 12 months (TTM)?
Celldex Therapeutics, Inc. EPS is -2.72 EUR over the trailing 12 months.
Which sector does the Celldex Therapeutics, Inc. company belong to?
The Celldex Therapeutics, Inc. sector is Healthcare.